Indrayani Biotech Q1 FY27 Results - Consolidated Growth, Weak Standalone

Revenue Growth 20pctRevenue DeclinePat Growth 25pctResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.1%Reaction day

₹10.09

prior close

₹10.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.8%-2.3% vs market

Other Agricultural Products peers, median of 59sector-1.6%-3.5% vs sector

On the reaction day the stock moved 2.3 pts less than Nifty Microcap 250 and 3.5 pts less than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

-3.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.1-2.8-2.3-1.6-3.5

Next day

-9.5-2.5-7.0-1.3-8.2

-13.1-1.7-11.4-1.1-12.0

-15.8-1.5-14.3-1.1-14.7

-14.1-0.8-13.3-0.2-13.9

-19.2-2.4-16.8-1.1-18.1

-18.0-3.4-14.7-3.0-15.0

15d

-20.2pendingpending-7.4-12.8

—————

UpDownMarket · Nifty Microcap 250Sector · Other Agricultural Products peers, median of 59Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone revenue fell to Rs 415.34 lakhs from Rs 668.57 lakhs YoY, while consolidated revenue grew 29.6 percent to Rs 3,770.55 lakhs from Rs 2,910.37 lakhs. Consolidated PAT jumped to Rs 54 lakhs from Rs 15.65 lakhs. Standalone PAT rose modestly to Rs 14.50 lakhs from Rs 12.77 lakhs. Auditor gave unmodified opinion. Board reconstituted Audit, Stakeholder and Rights Issue committees.

Likely market impact

Mixed bag. Weak standalone but strong subsidiary-led consolidated growth. Watch margin sustainability.